TB is a leading cause of mortality and morbidity globally, killing 1.4 million people every year, 1 and robbing millions more of health, hope, and prosperity. Current TB regimens are highly inadequate requiring 6-24 months to complete treatment. Protracted treatment times result in poor adherence and consequently promote the development of multi-drug resistant (MDR) and extensively drug resistant (XDR) TB. Treatment options for drug resistant TB are complex, toxic, and expensive, with less than 10% of MDR TB patients receiving proper care, and of those, more than a third failing to be fully cured. In this presentation, an overview of the Alliance’s operating model will be discussed. Additionally, a brief survey of the TB drug discovery landscape will be offered to illustrate areas of TB research globally. Finally, a case history on TBI-223 (a novel best-in- class oxazolidinone anti-tubercular agent advancing through preclinical candidate development) will be described as an illustration of TB Alliance’s strategic approach to contemporary drug discovery and development through innovation and partnerships.

Antitubercular 3-(4- aminophenyl)oxazolidin-2- ones: Progress towards better, safer TB agents

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.